Ochre Bio Taiwan Ltd
National Biotechnology Research Park (Resident company)
Pharmaceutical, Gene therapy
Ochre Bio, HQ’d in Oxford UK, develops genomic medicines that rejuvenate transplanted livers, ultimately with the goal of applying these therapies to treat fatty liver disease (NASH/NAFL) and other metabolic diseases. Ochre Bio Taiwan is Ochre’s first overseas research site, focusing on Target Discovery and Target Validation. The site will employ single-cell and spatial sequencing, advanced genomics, and high-throughput screening to identify disease-causing genes, and develop combination therapies together with Oxford HQ. In Jan 2021, Ochre Bio completed the largest genomic atlas of the liver, and is currently progressing multiple GalNAc-siRNA candidates toward the clinic.